Detalhes bibliográficos
| Resumo: | Background: Triple-negative breast cancer (TNBC) is associated with poor prognosis, and new treatment options are urgently needed. About 34%-39% of primary TNBCs show a low expression of human epidermal growth factor receptor 2 (HER2-low), which is a target for new anti-HER2 drugs. However, little is known about the frequency and the prognostic value of HER2-low in metastatic TNBC. Patients and methods: We retrospectively included patients with TNBC from five European countries for this international, multicenter analysis. Triple-negativity had to be shown in a metastatic site or in the primary breast tumor diagnosed simultaneously or within 3 years before metastatic disease. HER2-low was defined as immunohistochemically (IHC) 1+ or 2+ without ERBB2 gene amplification. Survival probabilities were calculated by the Kaplan–Meier method, and multivariable hazard ratios (HRs) were estimated by Cox regression models. Results: In total, 691 patients, diagnosed between January 2006 and February 2021, were assessable. The incidence of HER2-low was 32.0% [95% confidence interval (CI) 28.5% to 35.5%], with similar proportions in metastases (n = 265; 29.8%) and primary tumors (n = 425; 33.4%; P = 0.324). The median overall survival (OS) in HER2-low and HER2-0 TNBC was 18.6 and 16.1 months, respectively (HR 1.00; 95% CI 0.83-1.19; P = 0.969). Similarly, in multivariable analysis, HER2-low had no significant impact on OS (HR 0.95; 95% CI 0.79-1.13; P = 0.545). No difference in prognosis was observed between HER2 IHC 0/1+ and IHC 2+ tumors (HR 0.89; 95% CI 0.69-1.17; P = 0.414). Conclusions: In this large international dataset of metastatic TNBC, the frequency of HER2-low was 32.0%. Neither in univariable nor in multivariable analysis HER2-low showed any influence on OS. |
|---|
| Autores principais: | Gampenrieder, S. P. |
|---|
| Outros Autores: | Dezentjé, V.; Lambertini, M.; de Nonneville, A.; Marhold, M.; Le Du, F.; Cortés Salgado, A.; Alpuim Costa, D.; Vaz Batista, M.; Chic Ruché, N.; Tinchon, C.; Petzer, A.; Blondeaux, E.; Del Mastro, L.; Targato, G.; Bertucci, F.; Gonçalves, A.; Viret, F.; Bartsch, R.; Mannsbart, C.; Deleuze, A.; Robert, L.; Saavedra Serrano, C.; Gion Cortés, M.; Sampaio-Alves, M.; Vitorino, M.; Pecen, L.; Singer, C.; Harbeck, N.; Rinnerthaler, G.; Greil, R. |
|---|
| Assunto: | HER2-low metastatic OS prognosis real-world data triple-negative breast cancer Oncology Cancer Research SDG 3 - Good Health and Well-being |
|---|
| Ano: | 2023 |
|---|
| País: | Portugal |
|---|
| Tipo de documento: | artigo |
|---|
| Tipo de acesso: | acesso aberto |
|---|
| Instituição associada: | Universidade Nova de Lisboa |
|---|
| Idioma: | inglês |
|---|
| Origem: | Repositório Institucional da UNL |
|---|